Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2013 by Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor:
Collaborator:
Turgut Ozal University
Information provided by (Responsible Party):
Ayse Kirbas, Zekai Tahir Burak Maternity and Teaching Hospital
ClinicalTrials.gov Identifier:
NCT01931891
First received: August 26, 2013
Last updated: August 28, 2013
Last verified: July 2013
  Purpose

Preeclampsia affects 2% to 8% of all pregnancies and is a major cause of maternal morbidity an mortality worldwide.Althought the primary pathology leading to preeclampsia is remain not known, complex pathophysiologic pathways and mechanisms have been described.

New blood vessels evolve during angiogenesis and vasculogenesis, two physiological processes, that play a crucial role in embryogenesis and placentation. Structural alterations in the human umbilical cord, maternal spiral arteries can cause adverse fetal consequences.Pre-eclampsia is accompanied by an extensive remodelling of the ECM of the umbilical cord. Pre-eclamptic Wharton's jelly contains higher amounts of glycosaminoglycans in comparison to control tissue.

Matrixmetalloproteinases (MMPs) are a family of proteolytic enzymes that degrade various components of the extracellular matrix (ECM). A Disintegrin And Metalloproteinases (ADAMs) and ADAMs with Thrombospondin motifs (ADAMTS) are proteinases closely related to Matrix Metalloproteinases (MMPs). Dysregulation of ADAMs and ADAMTS expression have been reported in different types of pathologies such as cancer, osteoarthritis, neurodegenerative inflammation or asthma.

The role of ADAMTS in the pathomechanism of pre-eclampsia has not been studied until now. We therefore decided to compare the ADAMTS composition of the umbilical cord and placenta from newborns of mothers with pre-eclampsia with those with normal pregnancy.


Condition
Alterations of ECM in Umbilical Cord ECM in Preeclampisa
Alterations of ECM in Placenta in Preeclampisa

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by Zekai Tahir Burak Women's Health Research and Education Hospital:

Primary Outcome Measures:
  • severe preclampsia [ Time Frame: 34 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

umbilical cord placenta


Estimated Enrollment: 20
Study Start Date: July 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
prreclampsia

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

preeclamptic women

Criteria

-

Inclusion Criteria:

Clinical diagnosis of preeclampsia (diagnosed per ACOG criteria)

Exclusion Criteria:

known chronic disease multipl pregnancies

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01931891

Contacts
Contact: ayse kirbas, md 533-646-9213 ayseozdemirkirbas@hotmail.com

Locations
Turkey
Zekai Tahir Burak Maternity Hospital Recruiting
Ankara, Turkey
Contact: nuri danisman, md    306-5000      
Principal Investigator: ayse kirbas, md         
Sponsors and Collaborators
Zekai Tahir Burak Women's Health Research and Education Hospital
Turgut Ozal University
Investigators
Principal Investigator: ayse kirbas, md zekai tahir burak hospital
  More Information

No publications provided

Responsible Party: Ayse Kirbas, Zekai Tahir Burak Maternity and Teaching Hospital
ClinicalTrials.gov Identifier: NCT01931891     History of Changes
Other Study ID Numbers: ztb- wharton jelly
Study First Received: August 26, 2013
Last Updated: August 28, 2013
Health Authority: turkey: ministry of healt

Keywords provided by Zekai Tahir Burak Women's Health Research and Education Hospital:
preeclampsia, ADAMTS , wharton jelly, extracellüler matrix, placenta

ClinicalTrials.gov processed this record on September 18, 2014